The Tough Tech problem we are solving
Targeted delivery remains the biggest bottleneck in realizing the promise of gene therapy. Existing solutions (both viral and non-viral) lack tissue and/or cell specificity of delivery, which reduces their efficiency and increases toxicity risk. Immunogenicity of the vector limits the use of these approaches to "one-and-done", single dose therapies.
About our solution
STRM.BIO is leveraging megakaryocyte-derived extracellular vesicles (MVs) for safe, efficient, bone-marrow specific delivery in vivo. MVs deliver gene therapeutic cargo to the bone marrow (including to HSCs and T-cells) with little to no delivery observed in the liver and other tissues. MVs can be produced cost-effectively at scale and are immune silent, enabling repeat dosing when needed.